Logo
x

Search

Subscribe Now

obesity

Novo Nordisk's Wegovy (semaglutide) Receives CHMP's Recommendation for Approval to Treat Obesity

Novo Nordisk's Wegovy (semaglutide) Receives CHMP's Recommendation for Approval to Treat Obesity

  • November 12, 2021
AstraZeneca and Regeneron Collaborate to Research- Develop and Commercialize Therapies for Obesity

AstraZeneca and Regeneron Collaborate to Research- Develop and Commercialize Therapies for Obesity

  • July 27, 2021
Innovent Reports First Patient Dosing in P-II Clinical Trial for the Treatment of Obesity in China

Innovent Reports First Patient Dosing in P-II Clinical Trial for the Treatment of Obesity in China

  • June 16, 2021
Novo Nordisk's Wegovy (semaglutide- 2.4mg) Receives the US FDA's Approval for Weight Management in Adults with Obesity

Novo Nordisk's Wegovy (semaglutide- 2.4mg) Receives the US FDA's Approval for Weight Management in Adults with Obesity

  • June 7, 2021
Novo Nordisk Reports Results of Semaglutide from P-IIIa STEP 1 Trial in Patients with Obesity

Novo Nordisk Reports Results of Semaglutide from P-IIIa STEP 1 Trial in Patients with Obesity

  • May 14, 2021
Novo Nordisk to Initiate P-IIIa Study for Oral Semaglutide to Treat Obesity

Novo Nordisk to Initiate P-IIIa Study for Oral Semaglutide to Treat Obesity

  • April 22, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.